Seeking Alpha

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025

RARITAN, N.J., March 20, 2025 /PRNewswire/ -- Johnson & Johnson (JNJ) announced today that new data from its industry-leading oncology pipeline will be presented at the 2025 European Lung Cancer ...
ascopubs.org

Risk of pulmonary toxicities in patients with EGFR-mutant non-small cell lung cancer (NSCLC) treated with amivantamab: A systematic review and meta-analysis of phase 3 ...

Clinical characteristics of cancer-associated achalasia (CAA): A 25-year review from a cancer hospital. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...
Nasdaq

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer

Subcutaneous amivantamab is approved in Europe in combination with LAZCLUZE® for the first-line treatment of adult patients with advanced NSCLC with EGFR exon 19 deletions or exon 21 L858R ...